Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 3/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32341475 | 1.00 | ADRA1D (0.62) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL4944552 | 0.91 | TDP1 (0.60) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL10926815 | 0.89 | TDP1 (0.59) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL10925497 | 0.86 | ADRA1D (0.67) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL5781488 | 0.84 | ADRA1D (0.51) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL13510914 | 0.84 | TDP1 (0.65) | ADRA1DADRA1AADRA1BTDP1L3MBTL1 | |
| SCHEMBL10928016 | 0.83 | NR1H3 (0.53) | ADRA1DADRA1AADRA1BCASP3ALDH1A1 | |
| SCHEMBL10928019 | 0.83 | NR1H3 (0.53) | ADRA1DADRA1AADRA1BCASP3ALDH1A1 | |
| SCHEMBL5784952 | 0.83 | ADRA1D (0.64) | ADRA1DADRA1AADRA1BCASP3CA2 | |
| SCHEMBL21997738 | 0.83 | CASP3 (0.55) | ADRA1DADRA1AADRA1BCASP3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| CN-101528681-B | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT | 2013-01-30 | — | — | CN | disclosed |
| US-8034827-B2 | Phenanthridine derivatives as bradykinin antagonists | Richter Gegeon Nyrt. (HU) | 2011-10-11 | — | — | US | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| CN-101528681-A | New sulfonamide derivatives as bradykinin antagonists | RITCHER GEDEON NYRT (HU) | 2009-09-09 | — | — | CN | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| EP-1966142-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007072092-A2 | NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-20090270411-A1 | PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB2, BDKRB1, HRH2 | ADRA1D 364/4885ADRA1A 559/4885ADRA1B 428/4885 |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | ADRA1D 100/4885ADRA1A 216/4885ADRA1B 159/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ADRA1D 4445/4885ADRA1A 4409/4885ADRA1B 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.